These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 35296446)

  • 1. Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis.
    Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kimura T; Kanda J; Fukuda T; Atsuta Y; Ishiyama K
    Transplant Cell Ther; 2022 Jun; 28(6):323.e1-323.e9. PubMed ID: 35296446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis.
    Kurosawa S; Shimomura Y; Itonaga H; Najima Y; Kobayashi T; Ozawa Y; Kanda Y; Kako S; Kawakita T; Matsuoka KI; Maruyama Y; Ota S; Nakazawa H; Imada K; Kanda J; Fukuda T; Atsuta Y; Aoki J
    Bone Marrow Transplant; 2021 Dec; 56(12):3008-3015. PubMed ID: 34489555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation.
    Kamijo K; Shimomura Y; Shinohara A; Mizuno S; Kanaya M; Usui Y; Kim SW; Ara T; Mizuno I; Kuriyama T; Nakazawa H; Matsuoka KI; Kusumoto S; Maseki N; Yamaguchi M; Ashida T; Onizuka M; Fukuda T; Atsuta Y; Kondo E
    Ann Hematol; 2023 Mar; 102(3):651-661. PubMed ID: 36631705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients.
    Pan M; Wu Y; Yang L; Zhu P; Shi J; Lai X; Liu L; Zhao Y; Yu J; Huang H; Luo Y
    Ann Hematol; 2024 Aug; 103(8):3105-3119. PubMed ID: 38829409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
    Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
    Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies.
    Shimomura Y; Hara M; Yamamoto H; Uchida N; Kawakita T; Ashida T; Takada S; Ikeda T; Morishige S; Maruyama Y; Wake A; Ichinohe T; Fukuda T; Takanashi M; Atsuta Y; Ishikawa T
    Bone Marrow Transplant; 2021 Jul; 56(7):1691-1699. PubMed ID: 33658646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treosulfan- Versus Busulfan-based Conditioning in Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Single-center Retrospective Propensity Score-matched Cohort Study.
    Pasic I; Moya TA; Remberger M; Chen C; Gerbitz A; Kim DDH; Kumar R; Lam W; Law AD; Lipton JH; Michelis FV; Novitzky-Basso I; Viswabandya A; Mattsson J
    Transplant Cell Ther; 2024 Jul; 30(7):681.e1-681.e11. PubMed ID: 38648898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation.
    Mizuno S; Takami A; Kawamura K; Shimomura Y; Arai Y; Konuma T; Ozawa Y; Sawa M; Ota S; Takahashi S; Anzai N; Hiramoto N; Onizuka M; Nakamae H; Tanaka M; Murata M; Kimura T; Kanda J; Fukuda T; Atsuta Y; Yanada M
    Transplant Cell Ther; 2022 Nov; 28(11):775.e1-775.e9. PubMed ID: 35921987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
    Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
    Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
    Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
    Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
    Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
    Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity.
    Eapen M; Brazauskas R; Hemmer M; Perez WS; Steinert P; Horowitz MM; Deeg HJ
    Blood Adv; 2018 Aug; 2(16):2095-2103. PubMed ID: 30135184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT].
    Yuan J; Ren H; Qiu Z; Li Y; Wang M; Liu W; Xu W; Sun Y; Wang L; Liang Z; Dong Y; Ou J; Wang W; Yin Y; Cen X; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):475-9. PubMed ID: 26134011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis.
    Sibai H; Falcone U; Deotare U; Michelis FV; Uhm J; Gupta V; Kuruvilla J; Lipton JH; Seftel MD; Messner HA; Kim DDH
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2270-2275. PubMed ID: 27596129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
    Ueda T; Maeda T; Kusakabe S; Fujita J; Fukushima K; Yokota T; Shibayama H; Tomiyama Y; Kanakura Y
    Int J Hematol; 2019 Feb; 109(2):197-205. PubMed ID: 30448938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
    Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation.
    Arai N; Narita H; Kuroiwa K; Nagao K; Hayashi H; Kawamata N; Okamura R; Sasaki Y; Shimada S; Watanuki M; Kawaguchi Y; Yanagisawa K; Hattori N
    Transplant Proc; 2024 Oct; 56(8):1828-1835. PubMed ID: 39232926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.